Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Decitabine + FHD-286 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Decitabine | Dacogen | 5-aza-2-deoxycytidine | DNMT inhibitor (Pan) 5 | Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov). |
FHD-286 | FHD286|FHD 286 | FHD-286 inhibits SMARCA4 (BRG1) and SMARCA2 (BRM), which may lead to altered chromatin accessibility and decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND14, PMID: 38437498). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | sensitive | Decitabine + FHD-286 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of FHD-286 and Dacogen (decitabine) synergistically inhibited viability of acute myeloid leukemia cell lines harboring a KMT2A rearrangement in culture (PMID: 38437498). | 38437498 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|